Equity Overview
Price & Market Data
Price: $14.00
Daily Change: -$0.03 / 0.21%
Range: $13.69 - $14.14
Market Cap: $1,204,414,720
Volume: 584,795
Performance Metrics
1 Week: 2.92%
1 Month: -5.04%
3 Months: -1.67%
6 Months: 26.07%
1 Year: 9.03%
YTD: 20.07%
Company Details
Employees: 157
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.